University System of Maryland

Other

The Johns Hopkins University

Octamer, Inc.

Aurx, Inc.

Laure Aurelian

Cynthia Smith

Gary J Calton

Ernest Kun

Paul O Ts'o

Laura Scandurra

Aric Colunga

Jennifer Laing

Dana Perkins

The invention relates to a method of treating cancer, comprising administering to a subject in need thereof an effective amount of a HSV-2 virus, wherein the virus lacks protein kinase activity of ICP10. The invention further relates to pharmaceutical compositions comprising HSV-2 virus, wherein the virus lacks protein kinase activity of ICP10.

Methods and compositions for treating cancer

The invention relates to a method of treating neuronal apoptosis in a mammal using nucleic acid encoding HSV-2 ICP10PK, or a polypeptide encoded thereby. The invention further relates to a method of treating neuronal apoptosis in a mammal using ICP10PK in combination with a nucleic acid encoding bcl-2, or the polypeptide encoded thereby. The invention also relates to the use of ICP10PK and ICP10PK in combination with bcl-2 to treat non-neuronal diseases characterized by apoptosis.

Protein kinase domain of the large subunit of herpes simplex type 2 ribonucleotide reductase (icp 10pk) has anti-apoptotic activity

The present invention discloses a new vaccine composition for Herpes Simplex comprising a whole live HSV-2 virus having the oncogene deleted. Methods of using the vaccine composition are also included.

Vaccine composition for herpes simplex virus and methods of using

A method of treating HSV-2 infection which comprises administering to a host subject to said infection an effective amount of a polynucleotide of the formula polyrI.polyr(C.sub.12 U) where n is an integer from 4 to 29. The polynucleotide is advantageously administered intranasally.

Anti-viral and immuno stimulator polynucleotide duplex and use thereof

The present invention discloses a new immunogenic composition for Herpes Simplex comprising a whole live HSV-2 virus having the oncogene deleted. Methods of using the vaccine composition are also included.

Vaccine composition for herpes simplex virus and method of using

The present invention discloses a new vaccine composition for HSV-1 and HSV-2 comprising a whole live HSV-2 virus having the oncogene deleted. Methods of using the vaccine composition are also included.

A recombinant virus (ICP10.DELTA.RR) has been developed which is useful in a Western blot assay to specifically detect antibody to HSV-2, even the presence of co-existing antibody to HSV-1.

Herpes simplex virus type specific seroassay

The present method relates to the serological detection of herpes simplex virus type 2 (HSV-2) infection by means of reaction of a patient serum with a peptide specific to HSV-2 having the sequence Ala-Arg-Ser-Pro-Glu -Arg-Gln-Glu-Pro-Arg-Glu-Pro-Glu. The peptide may be further modified by the addition of a Cys or a biotin molecule. The peptide may be used in any of a number of assays including enzyme linked immunosorbent assay (ELISA), a radioimmunoassay (RIA), and other forms of immunoassay such as enzyme immunoblotting assay on a suitable adsorbent paper or an agglutination assay using the peptide composition as the antigen.

Serological assay for herpes

Unsubstituted or substituted 6-amino-1,2-benzopyrones are potent, selective and non-toxic inhibitors and suppressants of viral infections in a mammalian host. The compounds are particularly useful for treatment of AIDS, herpetic episodes and cytomegaloviral infections. The method of treatment of viral diseases by 6-amino-1,2-benzopyrones is described.

Growing community of inventors

Baltimore, MD, United States of America

Laure Aurelian